Tampa, FL., December 1, 2025 – Statement from Obesity Action Coalition (OAC) President and CEO Joe Nadglowski:

“The World Health Organization’s new recommendation for GLP-1 medications as part of a long-term treatment strategy for obesity is a significant milestone in recognizing obesity as a chronic, treatable disease. These medications, which can help reduce weight and lower the risk of obesity-related health complications, are now being recognized globally for their safety and effectiveness.

With prices starting to fall, coverage expanding under Medicare and clinical guidelines continuing to confirm their effectiveness and safety, it is time for private insurers to step up and make these medications accessible to the people who need them most. Obesity is a complex condition influenced by genetics, biology and environment—not a matter of willpower. Access to evidence-based care, including medications, is essential to supporting long-term health and reducing stigma.

The OAC calls on insurers and policymakers to act swiftly to remove financial or policy barriers and provide comprehensive coverage for these life-changing treatments. Everyone living with obesity deserves access to safe, effective care and society benefits when we treat obesity as the chronic disease it is.”

About the OAC
The OAC is a National nonprofit charity dedicated to helping individuals affected by obesity. The OAC was formed to bring together individuals struggling with weight issues and provide educational resources and advocacy tools.

CONTACT: For more information, please contact Gianna Toto, OAC Communications Coordinator, at gtoto@obesityaction.org